Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000492142 | SCV000581105 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-08-27 | criteria provided, single submitter | clinical testing | The p.L130P pathogenic mutation (also known as c.389T>C), located in coding exon 4 of the TP53 gene, results from a T to C substitution at nucleotide position 389. The leucine at codon 130 is replaced by proline, an amino acid with similar properties. This alteration was reported in an individual with breast cancer at 25 years of age, and thyroid cancer at 31 years of age (Wang PY et al. N. Engl. J. Med., 2013 Mar;368:1027-32), and was detected as a de novo finding in a teenage patient with acute lymphoblastic leukemia (ALL) (Ambry internal data). This variant is in the DNA binding domain of the TP53 protein and is reported to have loss of transactivation in yeast based assays (IARC TP53 database: Kato S et al. Proc. Natl. Acad. Sci. USA. 2003 Jul;100:8424-9). Studies conducted in human cell lines indicate this alteration is deficient at growth suppression (Kotler E et al. Mol. Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| Fulgent Genetics, |
RCV002475970 | SCV002779916 | pathogenic | Adrenocortical carcinoma, hereditary; Familial cancer of breast; Glioma susceptibility 1; Bone osteosarcoma; Li-Fraumeni syndrome 1; Nasopharyngeal carcinoma; Carcinoma of pancreas; Choroid plexus papilloma; Basal cell carcinoma, susceptibility to, 7; Hepatocellular carcinoma; Colorectal cancer; Bone marrow failure syndrome 5 | 2022-05-13 | criteria provided, single submitter | clinical testing |